IDEAYA Biosciences Files 8-K for 'Other Event' on Jan 4, 2024
Ticker: IDYA · Form: 8-K · Filed: Jan 12, 2024 · CIK: 1676725
| Field | Detail |
|---|---|
| Company | Ideaya Biosciences, Inc. (IDYA) |
| Form Type | 8-K |
| Filed Date | Jan 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $250.0 million, $158.9 million, $35.97, $58.7 million |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, corporate-governance, compliance
TL;DR
**IDEAYA Biosciences filed a routine 8-K, no major news.**
AI Summary
IDEAYA Biosciences, Inc. filed an 8-K on January 12, 2024, reporting an 'Other Event' that occurred on January 4, 2024. This filing primarily updates administrative information, such as confirming its status as a Delaware corporation and its listing on The Nasdaq Global Select Market under the ticker IDYA. For investors, this filing is largely administrative and does not contain new material financial or operational news that would immediately impact stock valuation, but it confirms the company's continued compliance and listing status.
Why It Matters
This filing is mostly administrative, confirming IDEAYA Biosciences' corporate details and listing on Nasdaq. It signals ongoing compliance but lacks new financial or operational news.
Risk Assessment
Risk Level: low — This 8-K filing is administrative and does not disclose any new risks or material changes to the company's operations or financial health.
Analyst Insight
A smart investor would note this as a routine administrative filing and not expect any immediate stock price movement. It's a confirmation of ongoing compliance rather than a catalyst for change.
Key Players & Entities
- IDEAYA Biosciences, Inc. (company) — the registrant filing the 8-K
- The Nasdaq Global Select Market (company) — the exchange where IDEAYA's common stock is registered
- Delaware (company) — state of incorporation for IDEAYA Biosciences, Inc.
FAQ
What was the specific 'Other Event' reported by IDEAYA Biosciences, Inc. in this 8-K filing?
The filing does not specify a particular 'Other Event' beyond the general category. It primarily serves to update or confirm administrative details about the company, such as its incorporation state and stock exchange listing, as of the event date of January 4, 2024.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 4, 2024, as stated in the 'Date of Report (Date of earliest event reported): January 4, 2024' section.
On which stock exchange is IDEAYA Biosciences, Inc.'s common stock registered?
IDEAYA Biosciences, Inc.'s common stock, with a $0.0001 par value per share and trading symbol IDYA, is registered on The Nasdaq Global Select Market.
What is the business address of IDEAYA Biosciences, Inc. as listed in the filing?
The business address of IDEAYA Biosciences, Inc. is 7000 Shoreline Court, Suite 350, South San Francisco, California 94080.
What is the Commission File Number for IDEAYA Biosciences, Inc.?
The Commission File Number for IDEAYA Biosciences, Inc. is 001-38915.
Filing Stats: 527 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-01-12 06:04:59
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IDYA The Nasdaq
- $250.0 million — aving aggregate gross proceeds of up to $250.0 million through Jefferies as sales agent. Dur
- $158.9 million — for aggregate estimated net proceeds of $158.9 million at a weighted average sales price of ap
- $35.97 — ed average sales price of approximately $35.97 per share under the at-the-market offer
- $58.7 million — . As of January 12, 2024, approximately $58.7 million of common stock remained available to b
Filing Documents
- d94559d8k.htm (8-K) — 22KB
- 0001193125-24-007021.txt ( ) — 140KB
- idya-20240104.xsd (EX-101.SCH) — 3KB
- idya-20240104_lab.xml (EX-101.LAB) — 18KB
- idya-20240104_pre.xml (EX-101.PRE) — 11KB
- d94559d8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events. On June 26, 2023, IDEAYA Biosciences, Inc. (the "Company") filed a Registration Statement on Form S-3 (File No. 333- 272936) under the Securities Act as an automatic shelf registration statement as a "well-known seasoned issuer", as defined in Rule 405 under the Securities Act. On June 26, 2023, the Company also entered into an Open Market Sales Agreement, or June 2023 Sales Agreement, with Jefferies LLC ("Jefferies") relating to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share, having aggregate gross proceeds of up to $250.0 million through Jefferies as sales agent. During the period from January 4, 2024 through January 11, 2024, the Company sold an aggregate of 4,553,781 shares for aggregate estimated net proceeds of $158.9 million at a weighted average sales price of approximately $35.97 per share under the at-the-market offering pursuant to the June 2023 Sales Agreement. As of January 12, 2024, approximately $58.7 million of common stock remained available to be sold under the at-the-market facility associated with the June 2023 Sales Agreement.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEAYA BIOSCIENCES, INC. Date: January 12, 2024 By: /s/ Yujiro Hata Yujiro Hata President and Chief Executive Officer